+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Does the modified Glasgow Prognostic Score (mGPS) have a prognostic role in esophageal cancer?



Does the modified Glasgow Prognostic Score (mGPS) have a prognostic role in esophageal cancer?



Journal of Surgical Oncology 113(7): 732-737



The modified Glasgow Prognostic Score (mGPS), which combines indices of decreased plasma albumin and elevated CRP, has reported independent prognostic significance in colorectal cancer, but its value in upper gastrointestinal cancer is unclear. The aim of this study was to assess the prognostic significance of mGPS in patients with operable esophageal malignancy. Patients undergoing resection with curative intent between January 2008 and June 2013 were included. The mGPS was scored as 0, 1, or 2 based on CRP(>10 mg/L) and albumin(<35g/L). The mGPS score (0 vs. 1/2 combined) was correlated with patient and tumor characteristics, and operative and oncologic outcomes. Two hundred and twenty-three patients were included. Median (range) follow-up was 21(12-70) months. The mGPS was 0 in 174 patients(78%). mGPS was significantly associated with positive nodal status(P = 0.008) and stage ≥III (P = 0.017). There was a significant improvement in overall survival in patients with mGPS = 0 (47.8 vs. 37.5 months, P = 0.014) but in multivariate analysis, only TNM-stage and nodal status were found to be independent prognostic indicators. mGPS is associated with advanced stage but has no independent prognostic significance and does not impact on operative outcomes. Consequently, this data does not support its routine application in patient selection or prognostication. J. Surg. Oncol. 2016;113:732-737. © 2016 Wiley Periodicals, Inc.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057654578

Download citation: RISBibTeXText

PMID: 27004839

DOI: 10.1002/jso.24225


Related references

High-sensitivity modified Glasgow prognostic score (HS-mGPS) Is superior to the mGPS in esophageal cancer patients treated with chemoradiotherapy. Oncotarget 8(59): 99861-99870, 2017

Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 142(6): 1285-1297, 2016

Onodera's prognostic nutritional index(PNI)and the modified Glasgow Prognostic Score(mGPS)in colorectal cancer surgery. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(10): 1273-1275, 2014

Predictive and Prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) in advanced gastric cancer patients treated with neoadjuvant chemotherapy. Zhonghua Zhong Liu Za Zhi 39(3): 195-200, 2017

The preoperative sensitive-modified Glasgow prognostic score is superior to the modified Glasgow prognostic score in predicting long-term survival for esophageal squamous cell carcinoma. Oncotarget 7(41): 67485-67494, 2016

The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor in patients with resectable gastric cancer. Oncology 87(4): 205-214, 2014

The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer. Oncotarget 9(97): 37008-37016, 2018

Prognostic Value of the Glasgow Prognostic Score or Modified Glasgow Prognostic Score for Patients with Colorectal Cancer Receiving Various Treatments: a Systematic Review and Meta-Analysis. Cellular Physiology and Biochemistry 51(3): 1237-1249, 2018

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). Gynecologic Oncology 148(1): 36-41, 2018

Changes in modified Glasgow prognostic score after neoadjuvant chemotherapy is a prognostic factor in clinical stage II/III esophageal cancer. Diseases of the Esophagus 29(2): 146-151, 2016

The modified Glasgow Prognostic Score (mGPS) is a good predictor of indication for palliative bypass surgery in patients with unresectable pancreatic and biliary cancers. International Journal of Clinical Oncology 19(4): 629-633, 2014

The modified glasgow prognostic score is an independent prognostic factor in patients with inoperable thoracic esophageal squamous cell carcinoma undergoing chemoradiotherapy. Journal of Cancer 5(8): 689-695, 2014

Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer. Urologic Oncology 37(3): 179.E19-179.E28, 2019

Preoperative Glasgow Prognostic Score as additional independent prognostic parameter for patients with esophageal cancer after curative esophagectomy. European Journal of Surgical Oncology 43(2): 445-453, 2017

Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer. Journal of Gastroenterology 49(6): 1040-1046, 2014